Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Olanzapine

"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."

Trial Locations (3)

N6A 5W9

Children's Hospital, London Health Sciences Centre, London

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

M5G1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

Pediatric Oncology Group of Ontario

OTHER

lead

The Hospital for Sick Children

OTHER

NCT02129478 - Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study | Biotech Hunter | Biotech Hunter